Bill Summary – FastDemocracy

SECOND REGULAR SESSION
                        HOUSE BILL NO. 2740
                               103RD GENERAL ASSEMBLY


                            INTRODUCED BY REPRESENTATIVE STEINMEYER.

     4420H.01I                                                                    JOSEPH ENGLER, Chief Clerk


                                                AN ACT
     To amend chapter 172, RSMo, by adding thereto one new section relating to rare pediatric
           disease research.


     Be it enacted by the General Assembly of the state of Missouri, as follows:

             Section A. Chapter 172, RSMo, is amended by adding thereto one new section, to be
 2   known as section 172.921, to read as follows:
             172.921. 1. As used in this section, the following terms mean:
 2           (1) "MURR", The University of Missouri research reactor;
 3           (2) "Radiotheranostics", a treatment approach using radioisotopes for both
 4   diagnosis and therapy;
 5           (3) "Rare pediatric disease", a life-threatening or chronically debilitating disease
 6   that affects fewer than two hundred thousand individuals under eighteen years of age in
 7   the United States;
 8           (4) "University", the University of Missouri system and its constituent
 9   campuses.
10           2. The university shall establish a governance board composed of:
11           (1) Representatives from the school of medicine, MURR, Ellis Fischel Cancer
12   Center, and NextGen Precision Health;
13           (2) One appointee from each chamber of the general assembly, appointed by the
14   speaker of the Missouri house of representatives and the president pro tempore of the
15   Missouri senate;
16           (3) One patient or family advocate representative; and
17           (4) One member representing a collaborating nonprofit or industry partner.

     EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is
     intended to be omitted from the law. Matter in bold-face type in the above bill is proposed language.
HB 2740                                    2

18        3. The governance board shall submit an annual public report to the general
19 assembly no later than December thirty-first of each year detailing:
20        (1) Research projects related to radiotheranostics in the treatment of rare
21 pediatric disease initiated and completed;
22        (2) Key outcomes achieved;
23        (3) Funds expended and leveraged; and
24        (4) Any legislative recommendations.
25        4. This section shall expire on June 30, 2030.
                                           ✔

Statutes affected: 
Introduced (4420H.01): 172.921